The Latest Breaking News from Big Pharma

Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'

China has pulled ahead of the United States in clinical drug development and supply chain, two of six domains measured in a June Cure Innovation Index survey, even as Big Pharma signs billion-dollar deals for Chinese-developed medicines.

Benzinga · Aug 13

‘It is okay not to be okay’: NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness

The hall-of-famer has partnered with Teva to raise awareness on Tardive Dyskinesia, a chronic movement disorder. He’s in good company with Serena & co.

Fortune · Jul 29

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

MarketBeat · Jun 11

A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

MarketBeat · Jan 14

6 Therapies for Chronic Pain That Big Pharma Doesn’t Want You to Know

Chronic pain affects millions of retirees, often stemming from arthritis, back problems, or long‑term injuries. Big Pharma promotes medications as the primary solution, but drugs...

Saving Advice · Nov 19, 2025

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.

MarketBeat · Oct 7, 2025

Big Pharma’s retreat: Is NHS pricing behind investor pullbacks?

Multinational pharmaceutical firms are pulling pack or pausing investments in the UK, blaming a lack of competitive drug pricing.

Euronews · Sep 30, 2025

The AI drug breakthrough is taking a long time to arrive for reasons that may have little to do with the technology’s limits

“No matter how much data you have, human biology is still a mystery,” one analyst said.

Fortune · Sep 12, 2025

Ozempic Is The New Botox And Big Pharma Is Printing Billions

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass $150 billion…

Benzinga · Sep 8, 2025

Tylenol In The Firing Line: RFK Jr. Autism Study Triggers Outrage, Market Rout And Big Pharma Panic

RFK Jr.'s autism study linking Tylenol in pregnancy to disorders sparks Big Pharma panic, political backlash and a fierce debate over corporate power.

International Business Times UK · Sep 6, 2025